Upstream Bio, Inc. (UPB) Price & Analysis

Compare

157 Followers

UPB Stock Chart & Stats

$26.97

-$0.08(-0.49%)

At close: Jan 08 4:00 PM EST

$26.97

-$0.08(-0.49%)

Day’s Range― - ―

52-Week Range$5.14 - $33.00

Previous CloseN/A

Volume32.37K

Average Volume (3M)388.50K

Market Cap

$1.50B

Enterprise Value$643.43M

Total Cash (Recent Filing)$372.43M

Total Debt (Recent Filing)$1.42M

Price to Earnings (P/E)―

Beta0.83

Next Earnings

Mar 18, 2026

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding54,038,590

10 Day Avg. Volume473,530

30 Day Avg. Volume388,499

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)1.80

Price to Sales (P/S)356.14

P/FCF Ratio-14.14

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue229.88

Enterprise Value/Gross Profit232.45

Enterprise Value/Ebitda-4.72

Forecast

1Y Price Target

$52.67

Price Target Upside95.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe upcoming phase 2 VALIANT trial data in severe asthma is expected to be a key catalyst for the stock, given the relative size of the asthma market.

Market PotentialVerekitug's sole program is targeting multi-billion-dollar indications like asthma and COPD, which have made other drugs into blockbusters.

Product DifferentiationVerekitug offers robust efficacy with a much improved dosing schedule by targeting the receptor, compared to other biologics for severe asthma.

Bears Say

Biotech RisksRisks to the rating and price target include safety, clinical, regulatory, competition, and financing inherent to all development stage biotechs including UPB.

Competitive RisksVerekitug may fail to produce competitive data or other TSLP and novel approaches in the clinic may raise the bar.

Efficacy Benchmark UncertaintyInvestors have debated whether the Phase II or Phase III results with Tezspire should serve as the 'bar' for efficacy for verekitug.

Upstream Bio, Inc. News

Upstream Bio initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Upstream Bio (UPB) with an Outperform rating and $43 price target Published first...

10d ago

UPB

3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

16d ago

UPB

CLSK

Upstream Bio initiated with an Outperform at Evercore ISI

Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio (UPB) with an Outperform rating and $40 price...

24d ago

UPB

3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts

Looking for top-rated biotech stocks to buy now? Recent analyst updates highlight three companies that have earned Strong...

30d ago

UPB

BNTX

Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on...

17d ago

UPB

Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by Evercore ISI analyst, Cory Kasimov. Cory...

24d ago

UPB

Upstream Bio Reports Progress in Respiratory Trials

Upstream Bio, Inc. ( ($UPB) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

UPB

Promising Outlook for Upstream Bio, Inc. Driven by Strong Drug Developments and Financial Health

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

1M ago

UPB

Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

1M ago

UPB

Upstream Bio files automatic mixed securities shelf

07:38 EST Upstream Bio (UPB) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

UPB

Upstream Bio reports Q3 revenue $683k, consensus $516.8k

“During this quarter we reached an important milestone in verekitug’s development and shared positive top-line results from VIBRANT,...

1M ago

UPB

Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

1M ago

UPB

Upstream Bio’s COPD Study: A Potential Game-Changer for Investors

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. (UPB) is conducting...

2M ago

UPB

Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. is conducting a...

2M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $33.00 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $1.50B.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 96 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.682 by $0.052.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.71.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 54,038,590 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.682. Following the earnings report the stock price went down -1.293%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

Upstream Bio, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-40.80%

Trailing 12-Months

Asset Growth

68.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$52.67

▲(95.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,32.52,36.06,39.6,43.14,46.68,50.22,53.76,57.3,60.839999999999996,64.38,67.92,71.46,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,30.802307692307693,32.62461538461538,34.44692307692308,36.269230769230774,38.09153846153846,39.91384615384615,41.73615384615385,43.55846153846154,45.38076923076923,47.20307692307692,49.02538461538462,50.84769230769231,{"y":52.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,29.82769230769231,30.675384615384615,31.523076923076925,32.370769230769234,33.21846153846154,34.066153846153846,34.91384615384615,35.761538461538464,36.60923076923077,37.456923076923076,38.30461538461539,39.152307692307694,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >